Genocea Biosciences Stock Forecast, Price & News

+0.04 (+2.04 %)
(As of 08/5/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume44,196 shs
Average Volume381,931 shs
Market Capitalization$108.87 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Genocea Biosciences logo

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.83 out of 5 stars

Medical Sector

716th out of 1,311 stocks

Biological Products, Except Diagnostic Industry

105th out of 180 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

Is Genocea Biosciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Genocea Biosciences stock.
View analyst ratings for Genocea Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Genocea Biosciences?

Wall Street analysts have given Genocea Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genocea Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Genocea Biosciences

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) issued its quarterly earnings data on Wednesday, July, 28th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.02.
View Genocea Biosciences' earnings history

How has Genocea Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNCA shares have increased by 9.3% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GNCA?

3 Wall Street analysts have issued twelve-month target prices for Genocea Biosciences' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Genocea Biosciences' stock price to reach $6.67 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts' price targets for Genocea Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 52, Pay $821.39k)
  • Dr. Thomas A. Davis, Chief Medical Officer (Age 57, Pay $631.72k)
  • Dr. Girish N. Aakalu Ph.D., Chief Bus. Officer (Age 46, Pay $536.42k)
  • Ms. Diantha Duvall, CFO & Sec. (Age 49)
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 49)
  • Ms. Jacquelyn L. Sumer, Chief Legal & Compliance Officer
  • Dr. Raymond D. Stapleton Jr., Exec. VP of Pharmaceutical Sciences & Manufacturing (Age 50)

What is William Clark's approval rating as Genocea Biosciences' CEO?

5 employees have rated Genocea Biosciences CEO William Clark on William Clark has an approval rating of 82% among Genocea Biosciences' employees.

Who are some of Genocea Biosciences' key competitors?

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $2.00.

How much money does Genocea Biosciences make?

Genocea Biosciences has a market capitalization of $108.87 million and generates $1.36 million in revenue each year. The biotechnology company earns $-43,710,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How many employees does Genocea Biosciences have?

Genocea Biosciences employs 72 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is

Where are Genocea Biosciences' headquarters?

Genocea Biosciences is headquartered at 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]

This page was last updated on 8/5/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.